

PEFR, FEF₂₅₋₇₅ and MVV In Type-1 Diabetic Male And Their Relationships With HbA_{1c}

Khan Mohammad Arif¹, Nasim Jahan², Nayma Sultana³

Abstract

Background: Diabetes mellitus is a chronic and debilitating disease. Its complications give rise to microvascular, macrovascular and neuropathic diseases which affect eyes, kidneys, heart, blood vessels and also lungs. So, there may be a relationship between type-1 diabetes and reduced lung function. **Objectives:** To observe PEFR, FEF₂₅₋₇₅ and MVV and their relationship with HbA_{1c} in type-1 diabetic male in Bangladesh. **Methods:** This cross-sectional study was carried out in the Department of Physiology, Sir Salimullah Medical College, Dhaka between 1st January and 31st December 2009. A total 30 type-1 diabetic male subjects, age 18-30 years were taken as study group. Another 30 apparently healthy age, sex, BMI and socioeconomic status matched non-diabetic persons were also included as control. For assessment of lung function PEFR, FEF₂₅₋₇₅ and MVV of all the subjects were measured by a digital spirometer. Again, to observe glycemic control serum blood glucose and glycosylated hemoglobin (HbA_{1c}) levels of diabetic patients were also measured by usual laboratory technique. Data were analyzed by unpaired 't' test and Pearson's correlation coefficient test. **Results:** PEFR (p<0.001), FEF₂₅₋₇₅ (p<0.001), and MVV (p<0.001) were significantly lower in type-1 diabetic patients in comparison to those of apparently healthy non-diabetic male. Again, their PEFR (p<0.05), FEF₂₅₋₇₅ (p>0.05), and MVV (p<0.05) were negatively correlated with HbA_{1c}. **Conclusion:** The lung functions were lower in type-1 diabetic male in comparison to those of non-diabetic counterpart and this reduction is mainly due to poor glycemic control.

Key words: Type-I diabetes mellitus, Lung function parameters, Glycosylated hemoglobin.

J Bangladesh Soc Physiol. 2013 June; 8(1): 16-20

For Authors Affiliation, see end of text.

<http://www.banglajol.info/index.php/JBSP>

Introduction

Diabetes mellitus is a clinical syndrome characterized by hyperglycemia due to absolute or relative deficiency of insulin¹. The incidence and prevalence of diabetes mellitus and its complications are increasing surprisingly throughout the world particularly in Indian subcontinent^{1,2}. Several distinct types of diabetes mellitus exist and are caused by a complex interaction of genetics and environmental factors³.

Received April 2011; Accepted November 2011

Type-1 diabetes mellitus caused by autoimmune destruction of beta cells in pancreas, resulting in total lack of insulin secretion. It is always symptomatic and shows classical features of hyperglycemia⁴. Although it can occur at any age but usually found in young people specially who are thin³. It is a serious, progressive multifactorial disease associated with a number of chronic complications, which include cardiovascular disease, nephropathy, neuropathy, retinopathy and lung damage⁵.

Several pathological changes may occur in the lungs of type-1 diabetic patients. Chronic hyperglycemia may cause reduction of diffusing capacity of lung due to thickening of alveolar epithelium and pulmonary capillary basal laminae because of microangiopathic process and nonenzymatic glycosylation of tissue proteins⁶. Similarly, because of structural changes, the volumes and elastic recoil of lung may also reduce in type-1 diabetic patients⁷. However, like other systemic disorders impairment of lung functions considered as a potential risk factor for type-1 diabetic patients⁸.

For assessment of lung functions PEFR, FEF₂₅₋₇₅ and MVV are usually measured⁹. In addition, glycosylated haemoglobin (HbA_{1c}%) can be estimated for the assessment of long term control of diabetes over the last 8 to 12 weeks and may increase in diabetic patients with pulmonary complications^{2,9}.

Peak expiratory flow rate (PEFR) is a better indicator of respiratory muscle strength, may decrease in type-1 diabetic patients. In a study some researchers found that patients with HbA_{1c}>10% showed a significant reduction in PEFR in type-1 diabetes mellitus. They also found that significant reduction was associated with diabetic nephropathy and neuropathy¹⁰.

Along with other lung function parameters, FEF₂₅₋₇₅ decreases in patients with diabetes mellitus. Some investigators in a study found that FEF₂₅₋₇₅ decreases in type-1 diabetes mellitus and it correlates with duration of disease, metabolic control and various complications of disease¹⁰. Moreover, Maximum Voluntary Ventilation (MVV) is a spirometric test, for measuring working capacity of respiratory muscle. This MVV may be decreased in diabetic patients due to impairment of respiratory muscle endurance¹¹.

Type-1 diabetes mellitus is likely to account for over 10% of the total diabetic cases¹² and the

incidence is increasing globally¹³. It is an incurable life long disease, it involves multiple systems with wide ranging and devastating complications including lung damage². Many studies of pulmonary functions on type-2 diabetic patients had been done by different researcher of different countries^{2,9} and also in our country¹⁴. However, no study has yet been done on lung function in type-1 diabetic patients in our country. Therefore, the present study was designed to observe PEFR, FEF₂₅₋₇₅ and MVV and their relationship with HbA_{1c} in type-1 diabetic male in Bangladesh. This study may help to create awareness among the physicians and the type-1 diabetic patients in Bangladesh regarding the damaging effect of diabetes on lung function. This may help earlier diagnosis and proper management of pulmonary complications in this group of patients.

Methods

This cross sectional study was done in the Department of Physiology, Sir Salimullah Medical College (SSMC) between 1st January 2009 and 31st December 2009. A total 30 type-1 diabetic male subjects, age 18-30 years were taken as study group (Group B). They were selected from out patient department of BIRDEM hospital. Another 30 apparently healthy age, sex, BMI and socioeconomic status matched non-diabetic persons were also included as control (Group A). They were selected from slum area of Kallyanpur, Dhaka City. All the subjects were belonged to lower socio- economic status. Subjects having history of asthma, any acute or chronic lung infection, heart disease, renal insufficiency (serum creatinine>1.5 mg/dl)¹⁵, or having any structural chest deformity were excluded from the study. Ethical permission was taken from the Institutional Ethics Committee (IEC) of SSMC.

Height and weight of the subjects were measured for calculation of BMI. After 8 to 14 hours of over night fasting, 5 ml of venous blood was collected at 8 am from every patient for estimation of fasting glucose, serum creatinine and HbA_{1c} level in the blood. A second blood sample was taken 2 hours after breakfast for estimation of blood glucose level. For the assessment of lung function PEFR, FEF₂₅₋₇₅ and MVV of all the subjects were measured. All of these tests were done by spirometric method by using a digital Spirometer (Spirobank G). Data were analyzed by Independent-Samples “t” test and Pearson’s correlation coefficient test as applicable.

Results

The anthropometric data of the study subjects are presented in Table I. Both the groups were matched for age and BMI. Serum creatinine and blood glucose levels are presented in Table II. All the subjects were with normal renal function.

Again, mean percentage of predicted values of PEFR, FEF₂₅₋₇₅ and MVV were significantly ($p < 0.001$) lower in group B, than those of group A. (Table III).

HbA_{1c} was negatively correlated with PEFR ($p < 0.05$), FEF₂₅₋₇₅ ($p > 0.05$) and MVV ($p < 0.05$). Fig 1,2,3.

Table I: Age and BMI in both groups (n=60)

Parameters	Group A (n=30)	Group B (n=30)	P value
Age (years)	23.43±3.41	23.63±3.38	0.820 ^{ns}
BMI (kg/m ²)	17.02±1.64	17.80±1.95	0.100 ^{ns}

Data are expressed as Mean ± SD. Statistical analysis was done by Independent-Samples “t” test.

Group A: Apparently healthy non-diabetic male
Group B: Type-I diabetic male
ns = not significant
n= Total number of Subjects

Table II : Serum creatinine, fasting blood glucose and blood glucose 2hr ABF in both groups (n=60)

Parameters	Group A (n=30)	Group B (n=30)	P value
Serum creatinine (mg/dl)	0.86±0.14	1.19±0.22	0.000***
Fasting blood glucose (mmol/L)	4.84±0.51	11.11±3.21	0.000***
2hr ABF (mmol/L)	7.14±0.32	16.38±4.54	0.000***

Data are expressed as Mean+SD. Statistical analysis was done by Independent-Samples “t” test.

Group A: Apparently healthy non-diabetic male

n = Total number of subjects.

Group B: Type-I diabetic male

*** = $p < 0.001$.

Table III: Percentage of predicted values of PEFR, FEF₂₅₋₇₅ and MVV in both groups (n=60)

Parameters	Group A (n=30)	Group B (n=30)	P value
PEFR %	93.07 ± 9.50	41.17 ± 20.39	0.000***
FEF ₂₅₋₇₅ %	98.07 ± 16.80	45.69 ± 22.58	0.000***
MVV %	86.00 ± 10.76	44.50 ± 15.25	0.000***

Data are expressed as Mean+SD. Statistical analysis was done by Independent-Samples “t” test.

Group A: Apparently healthy non-diabetic male
ns = Not significant

Group B: Type-I diabetic male

*** = $p < 0.001$

n=Total number of Subjects




Figure 1: Correlation of percentage predicted value of PEFR with HbA_{1c} in type-1 diabetic male (n=30)




Figure 2: Correlation of percentage predicted value of FEF₂₅₋₇₅ with HbA_{1c} in type-1 diabetic male (n=30)




Figure 3: Correlation of percentage predicted value of MVV with HbA_{1c} in type-1 diabetic male (n=30)

Discussion

In the present study, the lung function parameters in healthy subjects were almost similar to the findings reported by the various investigators from different countries^{10, 16} as well as in our country¹⁴. No abnormal findings of pulmonary function tests were detected in them.

In this study, mean percentage of predicted values of PEFR, FEF₂₅₋₇₅ and MVV were significantly ($p < 0.001$) lower in type 1 diabetic male than those of non-diabetic subjects. These findings are in consistent with those of some other researchers¹⁷.

Again, in this study HbA_{1c} was negatively correlated with PEFR ($p < 0.05$), FEF₂₅₋₇₅ ($p < 0.05$) and MVV ($p > 0.05$) in type-1 diabetic male. This observation is also similar to that of some other investigators⁹.

Impairment of pulmonary function parameters have been found in type-1 diabetic male. Again, close association of HbA_{1c} with deterioration of some of the pulmonary function parameters have been demonstrated in this group of subjects. However there are some postulated mechanisms, suggested by various investigators of different countries, which may imply the probable mechanism of these changes in lung functions in type-1 diabetic patients.

Chronic hyperglycemia may cause thickening of alveolar epithelium and pulmonary capillary basal laminae¹⁸, formation of fibrous tissue in lungs and chest wall¹⁹, autonomic as well as somatic neuropathy¹⁸, decreased production of NO⁵. These changes in lung tissue cause reduction of elastic recoil tendency of the alveoli and also reduction of lung volume¹⁹. In addition, diabetes mellitus is also associated with poor skeletal muscle strength due to increased protein catabolism²⁰. For this reason respiratory muscle endurance also decreases in diabetes mellitus¹¹.

In this cross-sectional study, the decrement of lung function parameters such as PEFR, FEF₂₅₋₇₅ and MVV in type-1 diabetic subjects is most

likely due to chronic hyperglycemia as the observed blood glucose level of them were higher. Again, negative correlation of lung function parameters with HbA_{1c} in the study group are also in favor of this finding. Chronic hyperglycemia causes microangiopathy which may causes glycation of bronchial tissue protein. It may also cause reduction of muscular strength and decrease relaxation of bronchial smooth muscle due to decreased production of NO. But the exact mechanism cannot be elicited from this type of study as histopathological examination of lung tissue and NO levels are not observed in this study.

Conclusion:

From this study, it may be concluded that lung function parameters like PEFR, FEF₂₅₋₇₅ and MVV decrease in type-1 diabetic male and the reduction is mainly due to poor glycemic control.

References :

1. WHO. Definition Diagnosis and Classification of Diabetes Mellitus and its complications. Report of a WHO Consultation Geneva: WHO. 1999.
2. Sinha S, Guleria R, Misra A, Pandey RM, Yadav R, Tiwari S. Pulmonary Functions In Patients With Type 2 Diabetes Mellitus. *Indian J Med Res* 2004; 119: 66-71.
3. Fauci AS, Kasper DL, Ligo DL, Braunwald E, Hauser SL, Jameson JL. Harrison's internal medicine. 17th edition. USA: Mcgrow-Hill companies, 2008.
4. Boon NA, Colledge NR, Walker BR, Hunter JAA. Davidson's Principle and Practice of Medicine. Edinberg: Churchill Livingstone, 2006: 808-847.
5. Meo SA, Ahmed J, Shah SFA, Regaiey AL, Hussain A, Rubean K. Effect of Duration of Disease on Ventilatory Function in an Ethjp Saudi Group of Diabetic Patients. *J Diabetes Sci Technol*. 2007; 1(5): 711-717.
6. Hsia CCW, Raskin P. Lung Function Changes Related to Diabetes Mellitus. *Diabet Tech Therapy*. 2007; 9(S1): 73-81.
7. Goldman MD. Lung Dysfunction in Diabetes. *Diabetes Care* 2003; 26(6): 1915-1918.
8. Ostrowski S, Barud W. Factors Influencing Lung Function: Are The Predicted Values For Spirometry Reliable Enough? Available from: <http://www.ipp.krakow.pl/journal/archive/0906s4/articles/31article.html>.
9. Davis WA, Knudman M, Kendall P, Grange V, Davis TME. Glycemic Exposure is Associated With Reduced Pulmonary Function in Type 2 Diabetes. *Diabetes Care* 2004; 27: 752-757.
10. Makker P, Gandhi M, Agarwal RP, Subir M, Kothari RP. *J Assoc Physician India* 2000; 48(10): 962-966.
11. Meo SA, Al-Drees AM, Arif M, Shah SFA, Al-Rubean K. Assessment of Respiratory Muscle Endurance in Diabetic Patients. *Saudi Med J* 2006; 27(2): 223-226.
12. Zimmet P, Alberti KG, Shan J, Tiwari S. Global and Social Implications of Diabetes Epidemic Nature 2001; 13414(6865): 782-787.
13. Onkamo P, Vaananen S, Karvonen M, Toumilehto J. Worldwide Increase in Incidence of Type 1 Diabetes- The Analysis of the Data on Published Incidence Trends. *Diabetologia* 1999; 42(12): 1395-1403. Online Type 1 Diabetes. Available from (Medlineplus/diabetestype1.html).
14. Ali O, Begum S, Begum N, Ali T, Ferdousi S. PEFR And FEV₂₅₋₇₅ In Type 2 Diabetes Mellitus And Their Relationships With Its Duration. *J Bangladesh Soc Physio* 2010 June; 5(1): 14-19.
15. Painter PC, Cope JY, Smith JH. Reference Information For The Clinical Laboratory. In: Burtis CA, Ashwood ER, editors. *Teitz Text Book of Clinical Chemistry*. Philadelphia: WB Saunders Company 1999; 1788-1846.
16. Davis TME, Knudman M, Kendall P, Hien VU, Davis WA. Reduced Pulmonary Function And Its Association In Type 2 Diabetes: The Fremantle Diabetes Study. *Diabet Research Clin Pract* 2000; 50: 153-159.
17. Verma S, Mumtaz G, Rattan PK. Assessment of Pulmonary Function in Patients with Diabetes Mellitus 2009; 11(2).
18. Villa MP, Cacciari E, Bernardi F, Cicognam A, Saiardi S, Zapulia F. Bronchial Reactivity in Diabetic Patients: Relationship to Duration of Diabetes and Degree of Glycemic Control. *Arch Ped Adoles Med* 1988; 142(7): 1708-1718.
19. Sandler M. Is The Lung a Target Organ in Diabetes Mellitus? *Arch Intern Med* 1990; 150: 1385-1388.
20. Lange P, Parner J, Schnohr P, Jensen G. Copenhagen City Heart Study: Longitudinal Analysis of Ventilatory Capacity in Diabetic And Non-diabetic Adults. *Eur Respir J* 2002; 20: 1406-1412.